Most Read

Set to open in 2029, the facility will cover approximately 466,000ft² and accommodate 1,000 employees. The centre will connect with other Novartis global research locations in Basel, Switzerland,

The company’s fourth quarter revenues increased 1% to $12.5bn, and its growth portfolio surged 16% to $7.4bn. BMS reported non-GAAP earnings per share (EPS) of $6.15 for the

This contract enables Apotex to seek marketing authorisation and distribute the product in the country through its branded medicine division, Searchlight Pharma, once regulatory approval is secured. Grünenthal

Under this agreement, Everest Medicines will make potential regulatory and commercial milestone payments of up to 1.04bn yuan ($149m) and an upfront payment of 200m yuan. Furthermore, Micot

The agreement aims to advance PrimeGen US’s stem cell research and development and will provide access to public markets capital for progressing clinical studies, regulatory activities, and potential

The designation covers adults with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutant, hormone receptor positive, HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression after treatment with

Samsung Biologics is set to become part of CEPI’s Vaccine Manufacturing Facility Network (VMFN), aiming to speed up the availability of protein-based vaccines and improve access during outbreaks

The deal grants Genentech exclusive global rights to develop and commercialise the selected RNAi programme. According to the contract, SanegeneBio will manage early development activities while Genentech will

The therapy aims to treat Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more. The CRL highlights deficiencies in human factors validation for Anaphylm, such